Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
NCT05233397 · RECRUITING · Phase 2
1 clinical trials found for Adamantinomatous Craniopharyngioma.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
There are 1 clinical trials listed for Adamantinomatous Craniopharyngioma. These span various phases from early safety studies to post-approval monitoring. Browse the trial listings below for details.
Look for trials with "Recruiting" status in the listings below, or visit our recruiting page to filter by condition. Each trial page includes decoded eligibility criteria to help you determine if you qualify.
Current Adamantinomatous Craniopharyngioma trials are distributed across: Phase 2 (1).